|
RS60310B1
(sr)
|
2010-08-10 |
2020-07-31 |
Rempex Pharmaceuticals Inc |
Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
EP2487159A1
(en)
|
2011-02-11 |
2012-08-15 |
MSD Oss B.V. |
RorgammaT inhibitors
|
|
US9012491B2
(en)
|
2011-08-31 |
2015-04-21 |
Rempex Pharmaceuticals, Inc. |
Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
WO2013064231A1
(en)
|
2011-10-31 |
2013-05-10 |
Phenex Pharmaceuticals Ag |
SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
|
|
EP2800745B1
(en)
|
2011-12-02 |
2020-02-12 |
Phenex Pharmaceuticals AG |
Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
|
|
JP6242868B2
(ja)
*
|
2012-05-08 |
2017-12-06 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
|
|
WO2013169704A2
(en)
*
|
2012-05-08 |
2013-11-14 |
Merck Sharp & Dohme Corp. |
TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
US9156858B2
(en)
|
2012-05-23 |
2015-10-13 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
SG11201407919WA
(en)
|
2012-05-31 |
2014-12-30 |
Phenex Pharmaceuticals Ag |
Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
|
|
US10561675B2
(en)
|
2012-06-06 |
2020-02-18 |
Rempex Pharmaceuticals, Inc. |
Cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
JO3215B1
(ar)
|
2012-08-09 |
2018-03-08 |
Phenex Pharmaceuticals Ag |
حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
WO2014026329A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026327A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026328A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026330A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
KR20150103270A
(ko)
|
2013-01-04 |
2015-09-09 |
렘펙스 파머수티클스 인코퍼레이티드 |
보론산 유도체 및 그의 치료적 용도
|
|
US9101638B2
(en)
|
2013-01-04 |
2015-08-11 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
US9241947B2
(en)
|
2013-01-04 |
2016-01-26 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
KR20150103269A
(ko)
|
2013-01-04 |
2015-09-09 |
렘펙스 파머수티클스 인코퍼레이티드 |
보론산 유도체 및 그의 치료적 용도
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP3027616B1
(en)
*
|
2013-07-30 |
2018-01-10 |
Boehringer Ingelheim International GmbH |
Azaindole compounds as modulators of rorc
|
|
EP3041821B1
(en)
*
|
2013-09-05 |
2018-05-30 |
Boehringer Ingelheim International GmbH |
Bicylic compounds as modulators of rorgamma
|
|
CN105531274A
(zh)
*
|
2013-09-11 |
2016-04-27 |
豪夫迈·罗氏有限公司 |
作为RORc调节剂的酮-咪唑并吡啶衍生物
|
|
BR112016008258A2
(pt)
|
2013-10-15 |
2017-10-10 |
Janssen Pharmaceutica Nv |
moduladores de ror?t de quinolinila
|
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
|
BR112016008215A2
(pt)
*
|
2013-10-15 |
2017-09-26 |
Janssen Pharmaceutica Nv |
moduladores de quinolinila ligados por alquila de roryt
|
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
|
JP6320523B2
(ja)
*
|
2013-10-15 |
2018-05-09 |
ヤンセン ファーマシューティカ エヌ．ベー． |
ＲＯＲγＴの第二級アルコールキノリニルモジュレータ
|
|
TW201605797A
(zh)
*
|
2013-12-10 |
2016-02-16 |
葛蘭馬克製藥公司 |
作為ror伽馬調節物的雙環雜芳基化合物
|
|
CN104530014B
(zh)
*
|
2013-12-25 |
2018-03-20 |
中国科学院广州生物医药与健康研究院 |
2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用
|
|
WO2015101928A1
(en)
*
|
2013-12-31 |
2015-07-09 |
Aurigene Discovery Technologies Limited |
Fused thiophene and thiazole derivatives as ror gamma modulators
|
|
AU2015210833B2
(en)
|
2014-02-03 |
2019-01-03 |
Vitae Pharmaceuticals, Llc |
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
JP2017507950A
(ja)
|
2014-02-27 |
2017-03-23 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
|
|
WO2015139621A1
(zh)
*
|
2014-03-18 |
2015-09-24 |
北京韩美药品有限公司 |
4-杂芳基取代的苯甲酸或苯甲酰胺类化合物
|
|
EP3139930B1
(en)
|
2014-05-05 |
2024-08-14 |
Melinta Therapeutics, Inc. |
Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
SI3140310T1
(sl)
|
2014-05-05 |
2020-01-31 |
Rempex Pharmaceuticals, Inc. |
Sinteza boronatnih soli in njihova uporaba
|
|
EP3140291A4
(en)
|
2014-05-05 |
2018-01-10 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
|
JP6523337B2
(ja)
|
2014-05-05 |
2019-05-29 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
|
|
WO2015179308A1
(en)
|
2014-05-19 |
2015-11-26 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
EA201692301A1
(ru)
|
2014-07-01 |
2017-06-30 |
Ремпекс Фармасьютикалз, Инк. |
Производные бороновой кислоты и их терапевтическое применение
|
|
JP6564029B2
(ja)
|
2014-10-14 |
2019-08-21 |
ヴァイティー ファーマシューティカルズ，エルエルシー |
Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
GB201419015D0
(en)
*
|
2014-10-24 |
2014-12-10 |
Orca Pharmaceuticals Ltd |
Compounds
|
|
US9845308B2
(en)
|
2014-11-05 |
2017-12-19 |
Vitae Pharmaceuticals, Inc. |
Isoindoline inhibitors of ROR-gamma
|
|
US9663515B2
(en)
|
2014-11-05 |
2017-05-30 |
Vitae Pharmaceuticals, Inc. |
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
WO2016081297A1
(en)
|
2014-11-18 |
2016-05-26 |
Rempex Pharmaceuticals, Inc. |
Cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
WO2016110821A1
(en)
|
2015-01-08 |
2016-07-14 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
CA2975997A1
(en)
*
|
2015-02-11 |
2016-08-18 |
Merck Sharp & Dohme Corp. |
Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2016128908A1
(en)
|
2015-02-12 |
2016-08-18 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
CN107614062A
(zh)
|
2015-03-12 |
2018-01-19 |
加利福尼亚大学董事会 |
用RORγ抑制剂治疗癌症的方法
|
|
US20180051041A1
(en)
|
2015-03-17 |
2018-02-22 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
WO2016164608A1
(en)
*
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
|
US10421751B2
(en)
|
2015-05-05 |
2019-09-24 |
Lycera Corporation |
Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
JP6549735B2
(ja)
*
|
2015-06-09 |
2019-07-24 |
アッヴィ・インコーポレイテッド |
核内受容体調節剤
|
|
WO2016198908A1
(en)
*
|
2015-06-09 |
2016-12-15 |
Abbvie Inc. |
Ror nuclear receptor modulators
|
|
AU2016276947A1
(en)
|
2015-06-11 |
2017-12-14 |
Lycera Corporation |
Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
|
|
DK3331876T3
(da)
|
2015-08-05 |
2021-01-11 |
Vitae Pharmaceuticals Llc |
Modulators of ror-gamma
|
|
ES2913048T3
(es)
*
|
2015-09-21 |
2022-05-31 |
Opna Immuno Oncology Sa |
Compuestos heterocíclicos y usos de estos
|
|
JP2018535958A
(ja)
*
|
2015-10-27 |
2018-12-06 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用
|
|
EP3368535B1
(en)
*
|
2015-10-27 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
|
|
US10344000B2
(en)
|
2015-10-27 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
|
|
MA53943A
(fr)
|
2015-11-20 |
2021-08-25 |
Vitae Pharmaceuticals Llc |
Modulateurs de ror-gamma
|
|
CN105412929B
(zh)
*
|
2015-11-27 |
2018-03-20 |
肖定璋 |
Il7r‑3’utr在调控维甲酸相关孤儿核受体表达中的应用
|
|
CN109071516B
(zh)
|
2015-12-15 |
2021-08-31 |
阿斯利康(瑞典)有限公司 |
新颖的化合物
|
|
KR102699906B1
(ko)
*
|
2016-01-21 |
2024-08-29 |
즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 |
브루톤 티로신 키나제 억제제
|
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
TWI757266B
(zh)
|
2016-01-29 |
2022-03-11 |
美商維它藥物有限責任公司 |
ＲＯＲ－γ調節劑
|
|
US9481674B1
(en)
|
2016-06-10 |
2016-11-01 |
Vitae Pharmaceuticals, Inc. |
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
ES2894251T3
(es)
|
2016-06-30 |
2022-02-14 |
Qpex Biopharma Inc |
Derivados de ácido borónico y usos terapéuticos de los mismos
|
|
WO2018084120A1
(ja)
*
|
2016-11-01 |
2018-05-11 |
学校法人東京理科大学 |
安息香酸誘導体及び脱水縮合剤、並びにエステル及びラクトンの製造方法
|
|
JP2020111510A
(ja)
*
|
2017-03-29 |
2020-07-27 |
科研製薬株式会社 |
インダゾール誘導体及びそれを含有する医薬
|
|
ES2924359T3
(es)
*
|
2017-04-11 |
2022-10-06 |
Sunshine Lake Pharma Co Ltd |
Compuestos de indazol sustituidos con flúor y usos de los mismos
|
|
IT201700041723A1
(it)
|
2017-04-14 |
2018-10-14 |
Italfarmaco Spa |
Nuovi inibitori selettivi di HDAC6
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
US20180352815A1
(en)
*
|
2017-06-12 |
2018-12-13 |
Cypress Bio-Tech Company Limited |
Multi-Application Insect Repellent Additive
|
|
WO2018229155A1
(en)
|
2017-06-14 |
2018-12-20 |
Astrazeneca Ab |
2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
|
|
CN115650976A
(zh)
|
2017-07-24 |
2023-01-31 |
生命医药有限责任公司 |
RORγ的抑制剂
|
|
WO2019018975A1
(en)
|
2017-07-24 |
2019-01-31 |
Vitae Pharmaceuticals, Inc. |
INHIBITORS OF ROR GAMMA
|
|
CN109485595B
(zh)
*
|
2017-09-12 |
2022-05-27 |
江苏恒瑞医药股份有限公司 |
亲水性基团取代的吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
|
|
MX2020003495A
(es)
|
2017-10-11 |
2020-09-18 |
Qpex Biopharma Inc |
Derivados de acido boronico y sintesis de los mismos.
|
|
AR117398A1
(es)
|
2018-03-12 |
2021-08-04 |
Abbvie Inc |
Inhibidores de la señalización mediada por tirosina cinasa 2
|
|
US12016868B2
(en)
|
2018-04-20 |
2024-06-25 |
Qpex Biopharma, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
BR112022022367A2
(pt)
|
2020-05-05 |
2023-01-10 |
Qpex Biopharma Inc |
Derivados e síntese de ácido borônico, formas polimórficas e usos terapêuticos dos mesmos
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
WO2023232870A1
(en)
|
2022-05-31 |
2023-12-07 |
Immunic Ag |
Rorg/rorgt modulators for the treatment of virus infections like covid-19
|